SYT Antibody (C-10): sc-515845

SYT Antibody (C-10) is a mouse monoclonal IgG2b antibody that detects SYT in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). SYT, or synovial translocation protein, plays a crucial role as a transcriptional coactivator, facilitating the expression of genes involved in cell growth and differentiation, which is particularly important in the context of synovial sarcomas. SYT features a conserved amino terminal SNH domain and a carboxy terminal QPGY domain, the latter of which acts as a transcriptional activating sequence. SYT is involved in the t(x;18) chromosomal translocation, leading to the formation of SYT-SSX fusion proteins that are implicated in the pathogenesis of synovial sarcomas. These fusions not only enhance transcriptional activity but also contribute to the oncogenic properties of tumors, making SYT a significant target for research and potential therapeutic interventions. The presence of SYT-SSX chimeras is a hallmark of synovial sarcomas, which account for up to 10% of soft tissue sarcomas and can be classified into biphasic and monophasic subtypes based on the specific fusion partner involved. anti-SYT antibody (C-10) is therefore an invaluable tool for studying the molecular mechanisms underlying these cancers and for developing targeted therapies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SYT Antibody (C-10) References:

1. Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus.  |  Thaete, C., et al. 1999. Hum Mol Genet. 8: 585-91. PMID: 10072425
2. A novel fusion gene, SYT-SSX4, in synovial sarcoma.  |  Skytting, B., et al. 1999. J Natl Cancer Inst. 91: 974-5. PMID: 10359553
3. Identification of a novel spliced variant of the SYT gene expressed in normal tissues and in synovial sarcoma.  |  Tamborini, E., et al. 2001. Br J Cancer. 84: 1087-94. PMID: 11308259
4. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma.  |  Sato, Y., et al. 2002. J Immunol. 169: 1611-8. PMID: 12133991
5. A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma.  |  Otsuka, S., et al. 2006. Cancer Genet Cytogenet. 167: 82-8. PMID: 16682293
6. Human synovial sarcoma proto-oncogene Syt is essential for early embryonic development through the regulation of cell migration.  |  Kimura, T., et al. 2009. Lab Invest. 89: 645-56. PMID: 19333234
7. Distinct subsets of Syt-IV/BDNF vesicles are sorted to axons versus dendrites and recruited to synapses by activity.  |  Dean, C., et al. 2012. J Neurosci. 32: 5398-413. PMID: 22514304
8. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group.  |  Kawaguchi, S., et al. 2012. Cancer Sci. 103: 1625-30. PMID: 22726592
9. Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.  |  Bloom, JE., et al. 2012. Expert Rev Vaccines. 11: 1401-4. PMID: 23252384
10. Detection of SYT-SSX mutant transcripts in formalin-fixed paraffin-embedded sarcoma tissues using one-step reverse transcriptase real-time PCR.  |  Norlelawati, AT., et al. 2016. Malays J Pathol. 38: 11-8. PMID: 27126659

The preferred SYT antibody is SYT Antibody (D-3): sc-390615.